A single injection of basic fibroblast growth factor (bFGF) into the vocal folds of patients with glottal insufficiency has been shown to be effective for a few years. However, the long-term therapeutic effect of a single injection of bFGF into the vocal folds has yet to be demonstrated. In this study, the therapeutic effect of a single injection of bFGF into the vocal folds was investigated over several years by monitoring patients for 36 months following this treatment.
Nineteen patients with glottal insufficiency received injections of bFGF diluted to 20 μg/mL in the superficial layer of the lamina propria of the bilateral vocal folds. The following parameters were evaluated at preinjection baseline and 6, 12, 18, 24, and 36 months later, and statistical comparisons were performed. The parameters evaluated were: the Grade, Rough, Breathy, Asthenic, and Strained (GRBAS) scale score; maximum phonation time; acoustic analysis; and glottal wave analysis (GWA) and kymograph edge analysis (KEA) using high-speed digital imaging (HSDI). The amplitude perturbation quotient (APQ) and period perturbation quotient (PPQ) were measured by acoustic analysis. The mean minimum glottal area during vocalization and mean minimum distance between the vocal folds were measured by GWA. The amplitudes of the bilateral vocal folds were measured by KEA.
Postinjection, the GRBAS scale score decreased from 6 months after injection, and maximum phonation time was prolonged. The mean minimum glottal area during vocalization and the mean minimum distance between the vocal folds calculated by GWA of HSDI decreased significantly after 6 months. These effects persisted until 36 months postinjection. APQ and PPQ derived from acoustic analysis tended to decrease, but not significantly. There was no clear change in the amplitudes of the bilateral vocal folds calculated by KEA of HSDI before and after injection.
These results suggest that the effects of a single injection of bFGF into the vocal folds persist for 36 months.
Abbreviations:APQ (amplitude perturbation quotient), bFGF (basic fibroblast growth factor), GRBAS (the Grade, Rough, Breathy, Asthenic, and Strained), GWA (glottal wave analysis), HSDI (high-speed digital imaging), KEA (kymograph edge analysis), MPT (maximum phonation time), PPQ (period perturbation quotient), SPL (sound pressure level)
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Voice
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- eutic potential of growth factors for aging voice.Laryngoscope. 2004; 114: 2161-2167
- Sulcus vocalis: a rational analytical approach to diagnosis and management.Annals Otol Rhinol Laryngol. 1996; 105: 189-200
- Single, high-dose local injection of bFGF improves thyroarytenoid muscle atrophy after paralysis.Laryngoscope. 2020; 130: 159-165
- A preliminary study of injectable collagen in human vocal fold augmentation.Otolaryngol Head Neck Surg. 1987; 94: 394-403
- Vocal cord augmentation with autogenous fat.Laryngoscope. 1992; 102: 495-500
- A meta-analysis of voice outcome comparing calcium hydroxylapatite injection laryngoplasty to silicone thyroplasty.Otolaryngol Head Neck Surg. 2013; 148: 197-208
- Crosslinked hyanuronan used as augmentation substance for treatment of glottal insufficiency: safety aspects and vocal fold function.Laryngoscope. 2002; 112: 2211-2219
- Therapy of unilateral vocal fold paralysis with polydimethylsiloxane injection laryngoplasty: our experience.J Voice. 2010; 24: 119-125
- Regeneration of aged vocal fold: first human case treated with fibroblast growth factor.Laryngoscope. 2008; 118: 2254-2259
- Age-related changes of collagenous fibers in the human vocal fold mucosa.Ann Otol Rhinol Laryngol. 2002; 111: 15-20
- Efficacy of a single dose of basic fibroblast growth factor: clinical observation for 1 year.J Voice. 2016; 30 (761.e11-761.e17)
- Clinical Examination of Voice.Springer Verlag, New York1981: 81-84
- Cross-linked hyaluronan versus collagen for injection treatment of glottal insufficiency: 2-year follow-up.Acta Oto-laryngologica. 2004; 124: 1208-1214
- Clinical experience with collagen injection of the vocal fold: a study of 155 patients.Auris Nasus Larynx. 2008; 35: 67-75
- Therapeutic efficacy of basic fibroblast growth factor in patients with vocal fold atrophy.Laryngoscope. 2020; 00: 1-6
- Effect of basic fibroblast growth factor on wound healing in healing-impaired animal models.Arzneimittelforschung. 1996; 46: 547-551
- The maintenance mechanism of the vocal fold tissue.The Larynx Japan. 2010; 22: 67-70
- Long-term benefits of regenerative therapy using FGF-2.J Jpn Soc Periodontol. 2012; 54: 38-45
- Injection of basic fibroblast growth factor for unilateral vocal cord paralysis.Acta Oto-Laryngologica. 2017; 137: 962-967
Published online: February 08, 2021
Accepted: January 11, 2021
© 2021 The Voice Foundation. Published by Elsevier Inc. All rights reserved.